Region:Asia
Author(s):Pratibha Grover
Product Code:KR991
Analyst at Ken Research in their latest publication “India Diagnostic Laboratories Market Outlook to FY’2025- By Government and Private Labs, By Radiology and Pathology, By Organized and Unorganized Players, By Business Model (Standalone, Hospital Based and Diagnostic Chains), By Cities (Tier I, Tier II and Tier III cities) and By Payment Method (Out of Pocket Expenditure, Insurance based and Corporate Spending” believe that the market is highly fragmented and there is a dire need for strict regulations. These regulations would help bring about uniformity along with high quality testing standards in the industry. The report further talks about the ecosystem of the diagnostic labs present in India along with a number of segmentations such as radiology and pathology, types of models used, organized and unorganized players and many more. It also provides an investment model for a franchise lab to open up in India. There have been a number of research projects focusing on innovative and less invasive forms of testing. Some of the challenges faced by this industry include price differentiation, lack of knowledge at the consumer end and lack of regulations. Despite the COVID-19 pandemic, this industry sees a bright future. People will be more aware of their health & lifestyle choices and hence, there would definitely be a rise in wellness/preventive testing, helping the diagnostic laboratory market of India to grow further in the coming years.
The market is highly fragmented with only four major PAN-India level players. It is still at its’ growing stage. However, the unorganized sector dominates the market’s revenue currently. The highest penetration of the labs is in Tier I cities, which is also the place for their reference labs. Digitalisation in the chain of diagnostics has helped remove mistakes from the time the samples have been collected to the last process of delivering the report to the customer. The major drivers for this market include the high elderly population and the shift from non-communicable to communicable diseases in India. Radiology test market has evolved over time with the advancement in the existing technology of imaging machines such as PET-scan which added more clarity in the diagnosis of the patient’s disease. Whereas for pathology, the segment has gained dominance in the market owing to the fact that it is the preferred line of diagnosis for the majority of diseases prevalent in India including infectious diseases.
The report explores segments such as government and private diagnostic labs within the country. It is the private diagnostic lab market which is further broken down into various segments. The market is dominated by unorganized players. Medical insurance in the country is currently focused upon the clinical side and not so much towards the diagnostic sector. As of now, majority of the payment is done through out of pocket expenditure. There are a number of standalone centers in the market which hold the highest share. The diagnostic chains are further split into regional and PAN-India level labs. Within the Indian market, there are a number of doctors who have tie ups with labs and hence the customers coming from a referral hold a prominent share in the overall market. The revenue earned by a lab from a referral customer is split between the doctor and the lab. In the future, it is expected that testing for wellbeing would increase as people are now making a conscious effort to stay fit, however testing for sick care would still dominate the market.
Due to lack of regulations, there are hardly any barriers to entry. As a result there are a number of labs which have opened throughout the country. Majority of them fail to follow protocols and lack accreditations. There is also a lack of price standardization due to which there is a high level of discrepancies between diagnostic test prices of Tier I and Tier III cities. The penetration of labs in the rural parts of India is also low. When compared to a developed market like that of UK wherein 80% of the medical expense is incurred by the government, India falls behind in both aspects and is inclined towards out of pocket expenditure.
The market structure is highly fragmented with unorganized players dominating the industry and has presence majorly in Tier-2 and Tier-3 cities. In the past few years, there have been a number of acquisitions and mergers with larger players acquiring smaller players helping the organized sector grow. It also facilitates a larger reach and more comprehensive test menus. There are majorly four PAN-India players which are well established in the market, they include Dr. Lal Pathlabs, Thyrocare Technologies, Metropolis Healthcare and SRL Diagnostics. These labs give utmost focus on research and development in order to introduce new and less invasive tests.
Government regulations are in focus which would help in streamlining the market in the coming years. As more companies enter the organized sector, there would be an increasing emphasis on the hub and spoke model in order to bring in volumes required for a commercial entity to survive in the market. Growth of 3D printing, which allows radiologists and clinicians to bring to life body parts and tumors which were previously available only as flat diagrams, will help revolutionize the market. India is set to increase its public health spending to 2.5% of its GDP by 2025 which would help cut down on out of pocket expenditure on healthcare services. This would be a major boost to the diagnostic sector of the industry. Consumer satisfaction would be a focus point in order to retain brand equity. Home sample collections are expected to further increase thereby bringing in convenience to the patient and facilitating further penetration of organized players in the market.
India Diagnostic Laboratories Market
Revenue Segmentation by Government and Private Labs
India Private Diagnostic Laboratories Market
Revenue Segmentation by Pathology and Radiology
Revenue Segmentation by Pathology
Revenue Segmentation by Radiology
Revenue Segmentation by Business Model
Revenue Segmentation by Diagnostic Chains
Revenue Segmentation by Tier I, II and III Cities
Revenue Segmentation by Organized and Unorganized Players
Revenue Segmentation by Type of Customers
Revenue Segmentation by Payment Method
Companies Mentioned:
2.1. Market Definitions
2.2.Abbreviations
2.3. Market Size and Modeling
5.1. Hub-and-Spoke Model
5.2. Customer Reach Out Model for Diagnostic Chains
6. India Diagnostic Laboratories Market Pricing Analysis
6.1. Government Initiative to Reduce Out of Pocket Expenditure
8.1. By Government and Privately Owned Diagnostic Laboratories, FY’2020
9.1. By Radiology and Pathology Laboratories, FY’2020
9.2. By Business Model (Standalone Centers/Polyclinics, Hospital Based Labs and Diagnostic Chains), FY’2020
9.3. By Diagnostic Chains (Regional Chains and Large PAN-India Labs) FY’2020
9.4. By Tier I, Tier II, and Tier III Cities, FY’2020
9.5. By Organized and Unorganized Players, FY’2020
9.6. By Type of Customers (Referrals, Walk Ins and Corporate Clients), FY’2020
9.7. By Cause for Testing (Sick Care and Wellness), FY’2020
9.8. By Payment Method (Out of Pocket Expenditure, Corporate Spending and Insurance), FY’20
10.1. India Private Pathology Tests Market Size By Revenue, FY’2020
10.2. India Pathology Tests Market Segmentation By Type of Pathology Tests (Clinical Biochemistry, Hematology, Surgical Pathology, Histopathology, Clinical Microbiology and Molecular Biology), FY’2020
11.1. India Private Radiology Tests Market Size By Revenue, FY’2020
11.2. India Private Radiology Tests Market Segmentation By Type of Tests (X-Rays, Sonography, MRI, CT Scans, Mammography and PET), FY’2020
13.1. Advancements in Technology
13.2. Collaboration of Diagnostic Healthcare Service Providers with Corporate Entities
13.3. Increasing Penetration of Medical Insurance
13.4. Regulating Telemedicine Industry Helping Diagnosis
13.5. Shift Towards Molecular Pathology and Genetics Testing
14.1. Growth of Population and Income Levels in India
14.2. Rise of Communicable and Non-Communicable Diseases
14.3. Usage of Laboratory Diagnostics as a tool in Clinical Practice
14.4. India Emerging as a Medical Tourism Destination
15.1. Lack of Regulations
15.2. High Equipment Cost
15.3. Lack of Knowledge Among the Consumers
15.4. Growing Operating Expenses
16.1. Interview with Mr. Arindam Haldar, Chief Executive Officer at SRL Limited
16.2. Interview with Dr. Kunal Sharma, SRL Reference laboratory and Consultant Oncopathologist- Fortis Hospitals, Bangalore
16.3. Interview with Mr. Indranil Roy Choudhury, Chief Operating Officer at Diagno Labs Pvt Ltd
18.1.Licenses and Other Regulations
20.1. SRL Diagnostics, FY’2020
20.2. Dr. Lal Pathlabs, FY’2020
20.3. Metropolis Healthcare Limited, FY’2020
20.4. Thyrocare Technologies Limited , FY’2020
20.5. Suraksha Diagnostics Pvt Ltd, FY’2020
20.6. Medall Healthcare Pvt. Ltd., FY’2020
20.7. Suburban Diagnostics, FY’2020
20.8. Neuberg Diagnostics, FY’2020
21.1. India Diagnostic Laboratories Market Cross Comparison for Major Players (Dr. Lal Pathlab, SRL Diagnostics, Metropolis Healthcare and Thyrocare Technologies Ltd ) Based on Accreditations, International Presence, Revenue in INR Cr (FY’2019) and Number of Lbs, FY’2020
21.2. India Diagnostic Laboratory Market Strengths and Weakness of Major Players (Dr. Lal Pathlabs, SRL Diagnostics, Metropolis Healthcare and Thyrocare Techbologies Limited), FY’20
21.3. Market Share of Major Players in India Private Organised Diagnostic Laboratories Market (Dr. Lal Pathlabs, SRL Diagnostics, Thyrocare Technologies, Metropolis Healthcare, Medall Healthcare Pvt Ltd., Suraksha Diagnostics Pvt Ltd, Suburban Diagnostics and Others), FY’2019
22.1. Revenue by Government and Private Diagnostic Laboratories, FY’2020 and FY’2025
22.2. Impact of COVID-19 on the Indian Diagnostic Laboratories Market
23.1. Revenue By Radiology and Pathology Tests, Fy’2020 and FY2025
23.1.Revenue By Pathology Tests (Clinical Biochemistry, Hematology, Surgical Pathology, Histopathology, Clinical Microbiology Molecular Biology and Others), Fy’2020 and FY2025
23.2. Revenue By Radiology Tests (X-Rays, Sonography, MRI, CT Scans, Mammography, PET and Others ), Fy’2020 and FY2025
23.3. Revenue By Tier I, Tier II and Tier III Cities, FY’2020 and FY’2025
23.4. Revenue By Organized and Unorganized Players, FY’2020 and FY’2025
23.5. Revenue By Business Model (Standalone Centers/Polyclinics, Hospital Based Labs and Diagnostic Chains), FY’2020 and FY’2025
23.1. Revenue by Diagnostic Chains (Regional Labs and Large PAN-India Labs), FY’2020 and FY’2025
23.2. Revenue by Type of Customers (Referrals, Walk Ins and Corporate Clients) FY’2020 and FY’2025
23.3. Revenue By Cause for Testing (Wellness and Sick-Care) FY’2020 and FY’2025
Revenue by Payment Method ( Out of Pocket Expenditure, Insurance and Corporate Spending ) FY’2020 and FY’2025
24.1.Krsnaa Diagnostics – Sustainable PPPs
24.2. Healthians- Asset Light Model
Contact Us
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.